Summary Six hundred and sixty-three patients were followed with serial serum CEA measurements in addition to routine clinical surveillance after radical resection of colorectal carcinoma. Of 626 available for analysis, 366 (58.4%) remained clinically free of recurrence and had a normal CEA (<20ngml-1) throughout and 89 (14.2%) had a temporary non-progressive rise in CEA with no evidence of secondary disease. Of 171 patients who developed proven or suggestive recurrence, 114 had a preceding rise in the serum CEA and in further 21 the CEA rose simultaneously with recurrence. In 36 patients secondary disease was detected while the CEA was still within normal limits. CEA was more effective as an early index of distant metastasis, thus in 76% of those patients with a preceding rise in CEA, the secondary disease was disseminated, whereas only 20% had localised recurrence. The pattern of rise in CEA was of no practical value in distinguishing localised from distant recurrence.
When carcinoembryonic antigen (CEA) was first identified by Gold & Freedman (1965a, b) it was thought to be specific for gastrointestinal neoplasms and foetal tissues. The development of a serum assay by Thompson et al. (1969) appeared to offer a blood test which would be of value in the diagnosis of alimentary cancers. Much of the initial enthusiasm for the test evaporated as it became apparent that serum CEA testing lacked specificity and sensitivity (Sugarbaker et al., 1976; Sorokin et al., 1974) and it has since been shown to be of minimal value in the primary diagnosis of gastrointestinal disease (Hine et al., 1978) . However, in the post-operative surveillance of patients who have had radical resections of colorectal carcinomas, several studies have shown that a rise in the serum CEA precedes clinical recurrence in the majority of cases (Sorokin et al., 1974; Mach et al., 1974; Booth et al., 1974; Herrera et al., 1976; Wood et al., 1978) . In some instances the lead-time has been up to 29 months (Sorokin et al., 1974) . Generally, these studies have been performed in units specialising in the follow-up of large bowel cancer and the aim of the present study was to assess the usefulness of serum CEA testing alongside routine surveillance in general surgical clinics.
Patients and methods
The study included 663 patients (367 males, 296 females) who had undergone radical surgery for colorectal carcinoma. In 290 the primary was in the rectum or rectosigmoid and in 373 it was colonic or caecal. Squamous cell carcinomas of the anus were excluded as were tumours originating in the appendix. Thirty-five surgeons from 8 different hospitals in the West Midlands contributed cases. All patients were under 70 years of age at the time of surgery (mean age 59.0 years) and CEA screening was usually commenced between 3 and 6 months after operation, although some individuals were admitted to the trial when resection had been performed up to 3 years previously. Histological grading of the primary tumour (Dukes, 1932) al. (1972) . The inter-and intra-assay variation of the method was found to be < 10%. An upper limit of 15ngml-P will include 99% of a normal population and in the present study a level of >20 ng ml-I was regarded as abnormal.
Patients in whom routine screening showed a CEA concentration of > 20 ng ml-1 were recalled to clinic within 2 (Hine & Dykes, 1984) .
Results
Of the 663 patients in the screening programme 37 were excluded from the final analysis (Table I) In the 62 patients where early recurrence after the CEA rise prevented inclusion in the therapeutic study, the lead time was longer when the disease was disseminated than when there was local recurrence (Table III) . The rate of rise was shown that a CEA rise was the first indication of recurrence in the majority of patients developing secondary disease (Mach et al., 1974; Booth et al., 1974; Herrera et al., 1976) . In the present study there was a proven or suggestive recurrence rate of 27.3% after a mean follow-up of 39.7 months. Birmingham Regional Cancer Registry figures show an uncorrected mortality rate of -52% at 40 months after diagnosis of radically treated colorectal cancer (Waterhouse, 1974) . Mortality must of necessity be lower than recurrence, and the substantial difference between these results is surprising. There appear to be three possible explanations for this difference. First, some of the surgeons did not enter all eligible patients into the study and there could, therefore, be some patient selection, but this deficiency was neither great nor frequent and seems unlikely. Second, the surgeons participating in the study were clearly interested in bowel cancer and the results may be better than the regional average, though the difference is large for this explanation. Third, there was a restriction on entry in that no patient entered the trial until at least 3-months had elapsed from the date of operation. Early post-operative deaths are excluded therefore from our figures. Furthermore, a few individuals were entered up to 3-years postoperatively when the rate of recurrence has dropped markedly. Thus, our figures are not compatible with those of the Cancer Registry and the present data may reasonably be regarded as representative.
Temporary, non-progressive elevations of CEA were seen in 14.2% of patients under surveillance and the patient in whom a progressive rise in CEA gave false information about recurrent disease is probably an extreme example of this same phenomenon. The problem of false positive rises in CEA has been recognised before (Rittgers et al., 1978) . Lowering the pathological level may enable earlier treatment to be given but more false positives would be expected. On the other hand, raising the pathological level to increase the specificity of the test would greatly reduce the yield from CEA surveillance. In this study, strict criteria of two determinations greater than 35 ng ml-1 and progressively rising have been enforced. This produced one false positive in 114 which may be regarded as an acceptable degree of specificity.
The potential benefit of any system of surveillance lies in allowing an improvement in therapy. In colorectal cancer this can only mean either early detection and removal of local recurrence or metachronous tumour, or more effective chemotherapy in disseminated disease. Moertel et al. (1978) believe the CEA test to be of little value in predicting locally recurrent lesions, a view that has more recently been challenged (Staab et al., 1978) . In this latter study, analysis of the rising CEA curves suggested that slow rises were associated with local disease, whereas faster rises indicated dissemination. Wood et al. (1980) also found that if a rising CEA remained below 75 ng ml-for at least 12 months, the site of recurrence was likely to be local, whereas in patients with metastatic disease serum concentrations reached 100 ng ml1 within 6 months of the first raised level. The present prospective study, however, suggests that this information may be of little practical value in the selection of patients for second-look laparotomy since in two thirds of those with localised recurrence the CEA trend was not apparent at the time the tumour became clinically obvious and in the 6 patients where the rate of rise was determined it was rapid in two. Faced with this uncertainty, the clinician would do better to use more conventional methods of establishing the presence of local disease when asymptomatic patients develop elevated CEA concentration. Nevertheless, in this study 26 patients with localised recurrence or a second primary had a preceding rise in CEA. Having established the presence of disease and assessed the operability some such patients may benefit from further surgery.
The present results, however, do confirm that progressive elevation of serum levels generally indicates disseminated disease, most commonly hepatic. It would appear more logical to consider a systemic approach such as chemotherapy when a significant rise occurs in serum CEA concentration. In advanced disease a clinical response rate to chemotherapy of over 40% has been reported (Moertel et al., 1975 ) although this has not been matched by an improvement in survival of treated patients (Buroker et al., 1978) . In a study from our unit when cytotoxic therapy was given at the earliest evidence of recurrence, as indicated by a rise in CEA, a similar picture emerged with no overall benefit to treated patients in terms of survival (Hine & Dykes, 1984) . However, a subgroup of patients who showed a significant fall in CEA seemed to derive clinical benefit from early therapy (Hine & Dykes, 1984) . Such patients together with those in whom surgically accessible disease is suggested by CEA demonstrate the possible value of a CEA surveillance programme after radical surgery for colorectal cancer.
